Targeted radionuclide therapy for bone metastases.
Recent advances in targeted radiotherapy offer a new approach for the management of metastatic bone pain. This paper will review the scientific basis for radionuclide therapy and will examine the evidence for clinical efficacy. The therapeutic potential of targeted radiotherapy can only be appreciated by comparison with established treatments. Alternative treatment options will, therefore, be discussed, to bring the potential advantages and hazards of targeted radiotherapy into perspective and to define its place in routine management.
Lewington
V J
VJ
Department of Nuclear Medicine, Southampton General Hospital, UK.
D000700:Analgesics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D003131:Combined Modality Therapy; D012968:Etidronic Acid / Q000627:therapeutic use; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010148:Intractable Pain / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D012211:Rhenium / Q000627:therapeutic use; D012493:Samarium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use
D000700:Analgesics; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D013326:Strontium Radioisotopes; C064573:rhenium-186(tin)etidronate; D012493:Samarium; D012211:Rhenium; C061972:samarium Sm-153 lexidronam; D012968:Etidronic Acid